{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:28:26Z","timestamp":1776274106841,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"narodowe centrum nauki","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ3\/02817"],"award-info":[{"award-number":["2019\/35\/B\/NZ3\/02817"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"narodowe centrum nauki","doi-asserted-by":"publisher","award":["2016\/21\/B\/NZ1\/00293"],"award-info":[{"award-number":["2016\/21\/B\/NZ1\/00293"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Duchenne muscular dystrophy (DMD) is an incurable disease, caused by the mutations in the\n                      <jats:italic>DMD<\/jats:italic>\n                      gene, encoding dystrophin, an actin-binding cytoskeletal protein. Lack of functional dystrophin results in muscle weakness, degeneration, and as an outcome cardiac and respiratory failure. As there is still no cure for affected individuals, the pharmacological compounds with the potential to treat or at least attenuate the symptoms of the disease are under constant evaluation. The pleiotropic agents, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, have been suggested to exert beneficial effects in the mouse model of DMD. On the other hand, they were also reported to induce skeletal-muscle myopathy. Therefore, we decided to verify the hypothesis that simvastatin may be considered a potential therapeutic agent in DMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Several methods including functional assessment of muscle function via grip strength measurement, treadmill test, and single-muscle force estimation, enzymatic assays, histological analysis of muscle damage, gene expression evaluation, and immunofluorescence staining were conducted to study simvastatin-related alterations in the\n                      <jats:italic>mdx<\/jats:italic>\n                      mouse model of DMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In our study, simvastatin treatment of\n                      <jats:italic>mdx<\/jats:italic>\n                      mice did not result in improved running performance, grip strength, or specific force of the single muscle. Creatine kinase and lactate dehydrogenase activity, markers of muscle injury, were also unaffected by simvastatin delivery in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice. Furthermore, no significant changes in inflammation, fibrosis, and angiogenesis were noted. Despite the decreased percentage of centrally nucleated myofibers in gastrocnemius muscle after simvastatin delivery, no changes were noticed in other regeneration-related parameters. Of note, even an increased rate of necrosis was found in simvastatin-treated\n                      <jats:italic>mdx<\/jats:italic>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, our study revealed that simvastatin does not ameliorate DMD pathology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13395-021-00276-3","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:22:47Z","timestamp":1630657367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Simvastatin does not alleviate muscle pathology in a mouse model of Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"11","author":[{"given":"Olga","family":"Mucha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Podkalicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kazir\u00f3d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Samborowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zef","family":"Dulak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-3560","authenticated-orcid":false,"given":"Agnieszka","family":"\u0141oboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"2","key":"276_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","volume":"1838","author":"B Constantin","year":"2014","unstructured":"Constantin B. Dystrophin complex functions as a scaffold for signalling proteins. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2014;1838(2):635\u201342. https:\/\/doi.org\/10.1016\/j.bbamem.2013.08.023.","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes."},{"issue":"1","key":"276_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96(1):253\u2013305. https:\/\/doi.org\/10.1152\/physrev.00007.2015.","journal-title":"Physiol Rev."},{"key":"276_CR3","doi-asserted-by":"crossref","unstructured":"\u0141oboda A, Dulak J. Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep. 2020;20.","DOI":"10.1007\/s43440-020-00134-x"},{"issue":"1","key":"276_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13395-019-0207-0","volume":"9","author":"I Bronisz-Budzy\u0144ska","year":"2019","unstructured":"Bronisz-Budzy\u0144ska I, Chwalenia K, Mucha O, Podkalicka P, Bukowska-Strakova K, J\u00f3zkowicz A, et al. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice. Skelet Muscle. 2019;9(1):22.","journal-title":"Skelet Muscle"},{"key":"276_CR5","first-page":"5(11)","volume":"4","author":"P Podkalicka","year":"2020","unstructured":"Podkalicka P, Mucha O, Bronisz-Budzy\u0144ska I, Kozakowska M, Pietraszek-Gremplewicz K, Cetnarowska A, et al. Lack of miR-378 attenuates muscular dystrophy in mdx mice. JCI Insight. 2020;4:5(11).","journal-title":"JCI Insight."},{"issue":"8","key":"276_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00018-019-03006-7","volume":"76","author":"P Podkalicka","year":"2019","unstructured":"Podkalicka P, Mucha O, Dulak J, Loboda A. Targeting angiogenesis in Duchenne muscular dystrophy. Cell Mol Life Sci. 2019;76(8):1507\u201328. https:\/\/doi.org\/10.1007\/s00018-019-03006-7.","journal-title":"Cell Mol Life Sci."},{"issue":"2","key":"276_CR7","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A, Viggiano E, D\u2019Ambrosio P, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121\u20135.","journal-title":"Acta Myol."},{"issue":"3","key":"276_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol."},{"issue":"2","key":"276_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/ars.2017.7435","volume":"29","author":"K Pietraszek-Gremplewicz","year":"2018","unstructured":"Pietraszek-Gremplewicz K, Kozakowska M, Bronisz-Budzynska I, Ciesla M, Mucha O, Podkalicka P, et al. Heme oxygenase-1 influences satellite cells and progression of Duchenne muscular dystrophy in mice. Antioxid Redox Signal. 2018;29(2):128\u201348.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"276_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2174\/1389450117666160401123600","volume":"18","author":"A Piechota-Polanczyk","year":"2017","unstructured":"Piechota-Polanczyk A, Jozkowicz A. The role of statins in the activation of heme oxygenase-1 in cardiovascular diseases. Curr Drug Targets. 2017;18(6):674\u201386. https:\/\/doi.org\/10.2174\/1389450117666160401123600.","journal-title":"Curr Drug Targets."},{"issue":"2","key":"276_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","volume":"72","author":"A Endo","year":"1976","unstructured":"Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72(2):323\u20136. https:\/\/doi.org\/10.1016\/0014-5793(76)80996-9.","journal-title":"FEBS Lett."},{"issue":"41","key":"276_CR12","doi-asserted-by":"publisher","first-page":"12864","DOI":"10.1073\/pnas.1509536112","volume":"112","author":"NP Whitehead","year":"2015","unstructured":"Whitehead NP, Kim MJ, Bible KL, Adams ME, Froehner SC. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy. Proc Natl Acad Sci USA. 2015;112(41):12864\u20139. https:\/\/doi.org\/10.1073\/pnas.1509536112.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"276_CR13","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14018","volume":"7","author":"MJ Kim","year":"2019","unstructured":"Kim MJ, Bible KL, Regnier M, Adams ME, Froehner SC, Whitehead NP. Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy. Physiol Rep. 2019;7(6):e14018. https:\/\/doi.org\/10.14814\/phy2.14018.","journal-title":"Physiol Rep."},{"issue":"3","key":"276_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/jcsm.12708","volume":"12","author":"F Amor","year":"2021","unstructured":"Amor F, Vu Hong A, Corre G, Sanson M, Suel L, Blaie S, et al. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle. 2021;12(3):677\u201393. https:\/\/doi.org\/10.1002\/jcsm.12708.","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"276_CR15","doi-asserted-by":"crossref","unstructured":"Verhaart IEC, Cappellari O, Tanganyika-de Winter CL, Plomp JJ, Nnorom S, Wells KE, et al. Simvastatin treatment does not ameliorate muscle pathophysiology in a mouse model for Duchenne muscular dystrophy. J Neuromuscul Dis. 2020;","DOI":"10.3233\/JND-200524"},{"issue":"8","key":"276_CR16","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/ar.24341","volume":"303","author":"JMG Finkler","year":"2020","unstructured":"Finkler JMG, de Carvalho SC, Santo Neto H, Marques MJ. Cardiac and skeletal muscle changes associated with rosuvastatin therapy in dystrophic mdx mice. Anat Rec (Hoboken). 2020;303(8):2202\u201312. https:\/\/doi.org\/10.1002\/ar.24341.","journal-title":"Anat Rec (Hoboken)."},{"issue":"1","key":"276_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","volume":"72","author":"L Bj\u00f6rkhem-Bergman","year":"2011","unstructured":"Bj\u00f6rkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol. 2011;72(1):164\u20135. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03907.x.","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"276_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314. https:\/\/doi.org\/10.1007\/s10557-005-5686-z.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"6","key":"276_CR19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","volume":"78","author":"G Fernandez","year":"2011","unstructured":"Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393\u2013403. https:\/\/doi.org\/10.3949\/ccjm.78a.10073.","journal-title":"Cleve Clin J Med."},{"issue":"1","key":"276_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"HV Ganga","year":"2014","unstructured":"Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6\u201315. https:\/\/doi.org\/10.1016\/j.ahj.2014.03.019.","journal-title":"Am Heart J."},{"key":"276_CR21","doi-asserted-by":"publisher","unstructured":"Hopewell JC, on behalf of the HPS S and H-TCG, Offer A, on behalf of the HPS S and H-TCG, Haynes R, on behalf of the HPS S and H-TCG, et al. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur Heart J. 2020;41(35):3336\u201342, DOI: https:\/\/doi.org\/10.1093\/eurheartj\/ehaa574.","DOI":"10.1093\/eurheartj\/ehaa574"},{"issue":"8","key":"276_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy--a genome wide study. N Engl J Med. 2008 Aug 21;359(8):789\u201399.","journal-title":"N Engl J Med."},{"issue":"4","key":"276_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","volume":"40","author":"BA Parker","year":"2012","unstructured":"Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012 Oct;40(4):188\u201394. https:\/\/doi.org\/10.1097\/JES.0b013e31826c169e.","journal-title":"Exerc Sport Sci Rev."},{"key":"276_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CIA.S29686","volume":"8","author":"S Bhardwaj","year":"2013","unstructured":"Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47\u201359. https:\/\/doi.org\/10.2147\/CIA.S29686.","journal-title":"Clin Interv Aging."},{"issue":"3","key":"276_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bcp.12687","volume":"80","author":"RB Iwere","year":"2015","unstructured":"Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015 Sep;80(3):363\u201371. https:\/\/doi.org\/10.1111\/bcp.12687.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"276_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40266-019-00736-y","volume":"37","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Albarqouni L, Curtis AJ, Breslin M, Nelson M. The safety and tolerability of statin therapy in primary prevention in older adults: a systematic review and meta-analysis. Drugs Aging. 2020;37(3):175\u201385. https:\/\/doi.org\/10.1007\/s40266-019-00736-y.","journal-title":"Drugs Aging."},{"issue":"5\u20136","key":"276_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10623320500476559","volume":"12","author":"J Dulak","year":"2005","unstructured":"Dulak J, Loboda A, Jazwa A, Zagorska A, D\u00f6rler J, Alber H, et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005;12(5\u20136):233\u201341. https:\/\/doi.org\/10.1080\/10623320500476559.","journal-title":"Endothelium."},{"issue":"1","key":"276_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.atherosclerosis.2006.03.015","volume":"187","author":"A Loboda","year":"2006","unstructured":"Loboda A, Jazwa A, Jozkowicz A, Dorosz J, Balla J, Molema G, et al. Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells. Atherosclerosis. 2006;187(1):26\u201330. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.03.015.","journal-title":"Atherosclerosis."},{"issue":"5","key":"276_CR29","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.4049\/jimmunol.165.5.2712","volume":"165","author":"MM Sadeghi","year":"2000","unstructured":"Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. The Journal of Immunology. 2000;165(5):2712\u20138. https:\/\/doi.org\/10.4049\/jimmunol.165.5.2712.","journal-title":"The Journal of Immunology."},{"key":"276_CR30","doi-asserted-by":"crossref","unstructured":"Aartsma-Rus A, van Putten M. Assessing functional performance in the mdx mouse model. J Vis Exp. 2014;85.","DOI":"10.3791\/51303"},{"issue":"1","key":"276_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13395-020-00255-0","volume":"10","author":"I Bronisz-Budzy\u0144ska","year":"2020","unstructured":"Bronisz-Budzy\u0144ska I, Kozakowska M, Podkalicka P, Kachamakova-Trojanowska N, \u0141oboda A, Dulak J. The role of Nrf2 in acute and chronic muscle injury. Skelet Muscle. 2020;10(1):35. https:\/\/doi.org\/10.1186\/s13395-020-00255-0.","journal-title":"Skelet Muscle."},{"issue":"2","key":"276_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ajpath.2017.10.017","volume":"188","author":"M Kozakowska","year":"2018","unstructured":"Kozakowska M, Pietraszek-Gremplewicz K, Ciesla M, Seczynska M, Bronisz-Budzynska I, Podkalicka P, et al. Lack of heme oxygenase-1 induces inflammatory reaction and proliferation of muscle satellite cells after cardiotoxin-induced skeletal muscle injury. Am J Pathol. 2018;188(2):491\u2013506. https:\/\/doi.org\/10.1016\/j.ajpath.2017.10.017.","journal-title":"Am J Pathol."},{"issue":"7","key":"276_CR33","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/cvr\/cvz236","volume":"116","author":"B Krist","year":"2020","unstructured":"Krist B, Podkalicka P, Mucha O, Mendel M, S\u0119pio\u0142 A, Rusiecka OM, et al. miR-378a influences vascularization in skeletal muscles. Cardiovasc Res. 2020;116(7):1386\u201397. https:\/\/doi.org\/10.1093\/cvr\/cvz236.","journal-title":"Cardiovasc Res."},{"issue":"1","key":"276_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2044-5040-4-21","volume":"4","author":"LR Smith","year":"2014","unstructured":"Smith LR, Barton ER. SMASH - semi-automatic muscle analysis using segmentation of histology: a MATLAB application. Skelet Muscle. 2014;4(1):21. https:\/\/doi.org\/10.1186\/2044-5040-4-21.","journal-title":"Skelet Muscle."},{"issue":"1","key":"276_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczynski","year":"1987","unstructured":"Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156\u20139. https:\/\/doi.org\/10.1016\/0003-2697(87)90021-2.","journal-title":"Anal Biochem."},{"issue":"24","key":"276_CR36","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1093\/hmg\/ddu366","volume":"23","author":"Y Hathout","year":"2014","unstructured":"Hathout Y, Marathi RL, Rayavarapu S, Zhang A, Brown KJ, Seol H, et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet. 2014;23(24):6458\u201369. https:\/\/doi.org\/10.1093\/hmg\/ddu366.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"276_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13395-015-0046-6","volume":"5","author":"S Schiaffino","year":"2015","unstructured":"Schiaffino S, Rossi AC, Smerdu V, Leinwand LA, Reggiani C. Developmental myosins: expression patterns and functional significance. Skeletal Muscle. 2015;5(1):22. https:\/\/doi.org\/10.1186\/s13395-015-0046-6.","journal-title":"Skeletal Muscle."},{"issue":"2","key":"276_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1006\/excr.1995.1041","volume":"216","author":"JE Anderson","year":"1995","unstructured":"Anderson JE, Mitchell CM, McGeachie JK, Grounds MD. The time course of basic fibroblast growth factor expression in crush-injured skeletal muscles of SJL\/J and BALB\/c mice. Exp Cell Res. 1995;216(2):325\u201334. https:\/\/doi.org\/10.1006\/excr.1995.1041.","journal-title":"Exp Cell Res."},{"issue":"1","key":"276_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcsm.12227","volume":"9","author":"J Siracusa","year":"2018","unstructured":"Siracusa J, Koulmann N, Banzet S. Circulating myomiRs: a new class of biomarkers to monitor skeletal muscle in physiology and medicine. J Cachexia Sarcopenia Muscle. 2018;9(1):20\u20137. https:\/\/doi.org\/10.1002\/jcsm.12227.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"5","key":"276_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3390\/biomedicines9050481","volume":"9","author":"P Podkalicka","year":"2021","unstructured":"Podkalicka P, Mucha O, Kazir\u00f3d K, Bronisz-Budzy\u0144ska I, Ostrowska-Paton S, Tomczyk M, et al. Age-dependent dysregulation of muscle vasculature and blood flow recovery after hindlimb ischemia in the mdx model of duchenne muscular dystrophy. Biomedicines. 2021;9(5):481. https:\/\/doi.org\/10.3390\/biomedicines9050481.","journal-title":"Biomedicines."},{"issue":"4","key":"276_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.vph.2005.11.007","volume":"44","author":"A Loboda","year":"2006","unstructured":"Loboda A, Jazwa A, Jozkowicz A, Molema G, Dulak J. Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin. Vascular Pharmacology. 2006;44(4):206\u201314. https:\/\/doi.org\/10.1016\/j.vph.2005.11.007.","journal-title":"Vascular Pharmacology."},{"issue":"2","key":"276_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0021-9150(03)00299-5","volume":"170","author":"M Frick","year":"2003","unstructured":"Frick M, Dulak J, Cisowski J, J\u00f3zkowicz A, Zwick R, Alber H, et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis. 2003;170(2):229\u201336. https:\/\/doi.org\/10.1016\/S0021-9150(03)00299-5.","journal-title":"Atherosclerosis."},{"issue":"1","key":"276_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Sch\u00e4cke","year":"2002","unstructured":"Sch\u00e4cke H, D\u00f6cke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23\u201343. https:\/\/doi.org\/10.1016\/S0163-7258(02)00297-8.","journal-title":"Pharmacol Ther."},{"issue":"4","key":"276_CR44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1734-1140(11)70601-6","volume":"63","author":"M Tomaszewski","year":"2011","unstructured":"Tomaszewski M, St\u0119pie\u0144 KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63(4):859\u201366. https:\/\/doi.org\/10.1016\/S1734-1140(11)70601-6.","journal-title":"Pharmacol Rep."},{"issue":"2","key":"276_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jse.2014.06.048","volume":"24","author":"ME Davis","year":"2015","unstructured":"Davis ME, Korn MA, Gumucio JP, Harning JA, Saripalli AL, Bedi A, et al. Simvastatin reduces fibrosis and protects against muscle weakness after massive rotator cuff tear. J Shoulder Elbow Surg. 2015;24(2):280\u20137. https:\/\/doi.org\/10.1016\/j.jse.2014.06.048.","journal-title":"J Shoulder Elbow Surg."},{"issue":"1","key":"276_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17453670610045669","volume":"77","author":"JP Dillon","year":"2006","unstructured":"Dillon JP, Laing AJ, Chandler JRS, Wang JH, McGuinness A, Redmond HP. Pravastatin attenuates tourniquet-induced skeletal muscle ischemia reperfusion injury. Acta Orthopaedica. 2006;77(1):27\u201332. https:\/\/doi.org\/10.1080\/17453670610045669.","journal-title":"Acta Orthopaedica."},{"issue":"1","key":"276_CR47","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41467-020-15971-w","volume":"11","author":"C P\u00e9ladeau","year":"2020","unstructured":"P\u00e9ladeau C, Adam N, Bronicki LM, Coriati A, Thabet M, Al-Rewashdy H, et al. Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles. Nature Communications. 2020;11(1):1990. https:\/\/doi.org\/10.1038\/s41467-020-15971-w.","journal-title":"Nature Communications."},{"issue":"12","key":"276_CR48","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis J-M, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nature Medicine. 1998;4(12):1441\u20134. https:\/\/doi.org\/10.1038\/4033.","journal-title":"Nature Medicine."},{"issue":"6","key":"276_CR49","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1172\/JCI37662","volume":"119","author":"SA Vetrone","year":"2009","unstructured":"Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 2009;119(6):1583\u201394. https:\/\/doi.org\/10.1172\/JCI37662.","journal-title":"J Clin Invest."},{"issue":"5","key":"276_CR50","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.ajpath.2016.01.002","volume":"186","author":"M Kuraoka","year":"2016","unstructured":"Kuraoka M, Kimura E, Nagata T, Okada T, Aoki Y, Tachimori H, et al. Serum osteopontin as a novel biomarker for muscle regeneration in duchenne muscular dystrophy. Am J Pathol. 2016;186(5):1302\u201312. https:\/\/doi.org\/10.1016\/j.ajpath.2016.01.002.","journal-title":"Am J Pathol."},{"issue":"5","key":"276_CR51","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1160\/TH12-05-0337","volume":"108","author":"AS Antonopoulos","year":"2012","unstructured":"Antonopoulos AS, Margaritis M, Shirodaria C, Antoniades C. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost. 2012;108(5):840\u20138. https:\/\/doi.org\/10.1160\/TH12-05-0337.","journal-title":"Thromb Haemost."}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-021-00276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-021-00276-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-021-00276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T08:24:42Z","timestamp":1630657482000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-021-00276-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s13395-021-00276-3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740754875.793597739","asserted-by":"object"}]},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"3 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with national and European legislation, after approval by the 2nd Institutional Animal Care and Use Committee (IACUC) in Krak\u00f3w, Poland (approval number: 323\/2018, 301\/2019, 79\/2021, and 170\/2021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}